Healthcare / BiotechnologyNasdaqCM
$1.43
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 51.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$2M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-151.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-8.0M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Net Income | $-8.0M | $-8.0M | $-13.2M | $-5.1M | $-12.7M | $-19.4M | $-10.9M | $-8.6M | $-11.6M | $-1.1M |
| EPS | -11.93 | -11.93 | -68.01 | -3.60 | -12.71 | -1.04 | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | — | — | — | — | — | $-12.0M | — | — | — | — |
| Returns | ||||||||||
| ROE | -151.2% | -151.2% | -324.4% | -125.5% | -388.6% | -553.7% | -273.3% | -120.3% | -261.9% | 114.2% |
| Growth & Yield | ||||||||||
| EPS Growth | 82.5% | 82.5% | -1789.2% | 71.7% | -1122.1% | — | — | — | — | — |
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.